| Title | Lymphatic dysfunction in lupus contributes to cutaneous photosensitivity and lymph node B cell responses. |
| Publication Type | Journal Article |
| Year of Publication | 2025 |
| Authors | Howlader MJ, Ambler WG, Chalasani MLatha S, Rathod A, Seltzer ES, Sim JHyun, Shin J, Schwartz N, Shipman WD, Dasoveanu DC, Carballo CB, Sevim E, Siddique S, Chinenov Y, Rodeo SA, Erkan D, Kataru RP, Mehrara BJ, Lu TT |
| Journal | J Clin Invest |
| Volume | 135 |
| Issue | 12 |
| Date Published | 2025 Jun 16 |
| ISSN | 1558-8238 |
| Keywords | Adult, Animals, Autoantibodies, Autoimmunity, B-Lymphocytes, Female, Humans, Lupus Erythematosus, Systemic, Lymph Nodes, Lymphatic Vessels, Male, Mice, Mice, Transgenic, Photosensitivity Disorders, Skin, Ultraviolet Rays |
| Abstract | Patients with systemic lupus erythematosus (SLE) are photosensitive, developing skin inflammation with even ambient ultraviolet radiation (UVR), and this cutaneous photosensitivity can be associated with UVR-induced flares of systemic disease, which can involve increased autoantibodies and further end-organ injury. Mechanistic insight into the link between the skin responses and autoimmunity is limited. Signals from skin are transmitted directly to the immune system via lymphatic vessels, and here we show evidence for potentiation of UVR-induced lymphatic flow dysfunction in SLE patients and murine models. Improving lymphatic flow by manual lymphatic drainage (MLD) or with a transgenic model with increased lymphatic vessels reduces both cutaneous inflammation and lymph node B and T cell responses, and long-term MLD reduces splenomegaly and titers of a number of autoantibodies. Mechanistically, improved flow restrains B cell responses in part by stimulating a lymph node fibroblastic reticular cell-monocyte axis. Our results point to lymphatic modulation of lymph node stromal function as a link between photosensitive skin responses and autoimmunity and as a therapeutic target in lupus, provide insight into mechanisms by which the skin state regulates draining lymph node function, and suggest the possibility of MLD as an accessible and cost-effective adjunct to add to ongoing medical therapies for lupus and related diseases. |
| DOI | 10.1172/JCI168412 |
| Alternate Journal | J Clin Invest |
| PubMed ID | 40261709 |
| PubMed Central ID | PMC12165800 |
| Grant List | R01 AI079178 / AI / NIAID NIH HHS / United States R21 AR081493 / AR / NIAMS NIH HHS / United States P30 CA008748 / CA / NCI NIH HHS / United States R01 AR084694 / AR / NIAMS NIH HHS / United States T32 AR071302 / AR / NIAMS NIH HHS / United States S10 OD019986 / OD / NIH HHS / United States T32 GM007739 / GM / NIGMS NIH HHS / United States |
Submitted by ljc4002 on November 10, 2025 - 9:43am
